Professional Grade Healthcare Products.
All Natural. All High Science.

Oculus Innovative Sciences, Inc.

About Oculus

Oculus Innovative Science is a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries. The company’s products, over 100 SKUs commercialized worldwide, are used to treat patients in advanced wound management, dermatology, women’s health and animal health; addressing the unmet medical needs of these markets—while raising the standard of patient care and lowering overall healthcare costs. The company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America.

We are a dynamic, fast growing healthcare company that designs, markets and sells pharmaceuticals, devices and nutritionals in more than 20 countries around the world.

What We Do
Our products embrace the breadth of life, from first breath to last, from newborns to aging adults, and improve the health of the people we serve.

Why We Are Here
We are here for the people we serve in their pursuit of better health.

What We Believe
We believe that our business can do well by doing good – by helping those we serve to get healthy, faster, our company will grow and prosper.

Oculus was incorporated as a privately held company in April 1999 as MicroMed Laboratories, Inc., with a focus on laboratory testing services for biotech and pharmaceutical companies.  In August 2001, the company changed its name to Oculus Innovative Sciences, broadening the company’s focus to include the development and eventual commercialization of the anti-infective Microcyn® Technology.  In January 2007, the company executed an IPO and became a publicly traded company on the NASDAQ.  In 2012, a new subsidiary, NVN Therapeutics, was launched, its purpose being the development of medicals foods for the dietary management of various disease states.  In February 2013, a second subsidiary, Ruthigen, Inc., was established for the purpose of developing next-generation drug candidates based upon an advanced Microcyn Technology formulation.